ContraFect to Present at ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance
August 22 2018 - 5:00PM
ContraFect Corporation (Nasdaq:CFRX), a
clinical-stage biotechnology company focused on the discovery and
development of protein and antibody therapeutics for
life-threatening, drug-resistant infectious diseases, today
announced the presentation of data on its lead drug candidate,
CF-301 (exebacase), at the European Society for Clinical
Microbiology and Infectious Diseases (ESCMID) / American Society
for Microbiology (ASM) Conference on Drug Development to Meet the
Challenge of Antimicrobial Resistance, to be held from September
4-7, 2018, in Lisbon, Portugal.
ContraFect will present data from its lead lysin
product candidate, CF-301 (exebacase), currently being studied in a
Phase 2 clinical study as a novel therapy for Staphylococcus aureus
(Staph aureus) bacteremia including endocarditis. These data
demonstrate a newly identified property of CF-301, which is the
ability to resensitize methicillin-resistant Staph aureus (MRSA) to
penicillin derivatives and first generation cephalosporins, both in
vitro and in the rabbit infective endocarditis model.
“We are excited by these new observations which
indicate that CF-301 can resensitize resistant strains of Staph
aureus to the antibiotics to which they had become resistant. These
data raise the possibility that CF-301 may have therapeutic utility
as a potential “resensitizing agent” to make resistant strains
susceptible again.” said Cara Cassino, M.D., Chief Medical Officer
and Executive Vice President of Research and Development at
ContraFect. “We are pleased to present these data at this meeting
as a potential new mechanism to combat and reverse antimicrobial
resistance and we continue to look forward to the results of our
Phase 2 clinical trial of exebacase, expected later this year.”
Presentation Details:
Presentation Title: Lysin
CF-301 (Exebacase) Resensitizes Methicillin-Resistant
Staphylococcus aureus (MRSA) to Penicillin Derivatives and First
Generation Cephalosporins Abstract
Number: 99
The abstract can be accessed through the ESCMID website.
Following the meeting, the presentation poster will be available on
the ContraFect website.
About ContraFect:
ContraFect is a biotechnology company focused on discovering and
developing therapeutic protein and antibody products for
life-threatening, drug-resistant infectious diseases, particularly
those treated in hospital settings. An estimated 700,000 deaths
worldwide each year are attributed to antimicrobial-resistant
infections. We intend to address life threatening infections using
our therapeutic product candidates from our lysin and monoclonal
antibody platforms to target conserved regions of either bacteria
or viruses (regions that are not prone to mutation). ContraFect's
initial product candidates include new agents to treat
antibiotic-resistant infections such as MRSA (Methicillin-Resistant
Staphylococcus aureus) and influenza. ContraFect’s lead product
candidate, CF-301, is currently in a Phase 2 clinical trial for the
treatment of Staphylococcus aureus (Staph aureus) bacteremia,
including endocarditis and is the first lysin to enter clinical
studies in the U.S. ContraFect is also conducting research
focused on the discovery of lysins to target Gram-negative
bacteria.
About CF-301 (exebacase):
CF-301 (exebacase) is a recombinant bacteriophage-derived lysin
with potent bactericidal activity against Staph aureus, a major
cause of blood stream infections, or bacteremia. CF-301 has the
potential to be a first-in-class treatment for Staph aureus
bacteremia. It has a novel, rapid, and specific mechanism of
bactericidal action against Staph aureus and does not impact the
body's natural bacterial flora. By targeting a conserved region of
the cell wall that is vital to bacteria, resistance is less likely
to develop to CF-301. Combinations of CF-301 with standard of care
antibiotics significantly increased bacterial killing and survival
in animal models of disease when compared to treatment with
antibiotics or CF-301 alone. In addition, in vitro and in vivo
experiments have shown that CF-301 is highly active against
biofilm-associated infections. CF-301 was licensed from The
Rockefeller University and is being developed at ContraFect. It is
the first lysin to enter clinical studies in the U.S.
Forward-Looking Statements:
This press release contains, and our officers and
representatives may make from time to time, “forward-looking
statements” within the meaning of the U.S. federal securities
laws. Forward-looking statements can be identified by words
such as “projects,” “may,” “will,” “could,” “would,” “should,”
“believes,” “expects,” “anticipates,” “estimates,” “intends,”
“plans,” “potential,” “promise” or similar references to future
periods. Examples of forward-looking statements in this release
include, without limitation, statements regarding our ability to
discover and develop protein and antibody therapeutics for
life-threatening, drug-resistant infectious diseases, CF-301 in
vivo and in vitro study results, including its ability to
resensitize methicillin-resistant Staph aureus to penicillin
derivatives and first generation cephalosporins, the timing of our
Phase 2 clinical trial results, our ability to address life
threatening infections using our therapeutic product candidates
from our lysin and monoclonal antibody platforms to target
conserved regions of either bacteria or viruses, whether our
initial product candidates can treat antibiotic-resistant
infections such as MRSA (Methicillin-resistant Staph aureus) and
influenza, our ability to continue research focused on lysins
targeting Gram-negative bacteria, whether CF-301 has potent
bactericidal activity against Staph aureus and whether it has the
potential to be a first-in-class treatment for Staph aureus
bacteremia, and statements regarding CF-301 data, including its
activity regarding biofilm-associated infections. Forward-looking
statements are statements that are not historical facts, nor
assurances of future performance. Instead, they are based on
ContraFect’s current beliefs, expectations and assumptions
regarding the future of its business, future plans, strategies,
projections, anticipated events and trends, the economy and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent risks, uncertainties and
changes in circumstances that are difficult to predict and many of
which are beyond ContraFect’s control, including those detailed in
ContraFect's filings with the Securities and Exchange
Commission. Actual results may differ from those set forth in
the forward-looking statements. Important factors that could cause
actual results to differ include, among others, our ability to
develop treatments for drug-resistant infectious diseases. Any
forward-looking statement made by ContraFect in this press release
is based only on information currently available and speaks only as
of the date on which it is made. Except as required by applicable
law, ContraFect expressly disclaims any obligations to publicly
update any forward-looking statements, whether written or oral,
that may be made from time to time, whether as a result of new
information, future developments or otherwise.
Investor Relations Contacts:
Michael MessingerContraFect CorporationTel: 914-207-2300Email:
mmessinger@contrafect.com
Matthew ShinsekiStern Investor RelationsTel: 212-362-1200Email:
matthew@sternir.com
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Apr 2023 to Apr 2024